CNS Pharmaceuticals, Inc.
CNSPHealthcare|Biotechnology|US
$3.92
-0.09 (-2.24%)
DCF Value
$7.67
Tangible Book / Share
$2.66
Cash / Share
$2.92
Financials
Financial Snapshot
Market Cap
$5.7M
Enterprise Value
-$14.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$16.7M
Cash & Investments
$20.0M
Net Cash
$20.0M
Free Cash Flow (TTM)
-$13.4M
Operating CF (TTM)
-$13.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$20.0M
Quarterly Burn
$3.4M
Monthly Burn
$1.1M
Est. Runway
~6.0 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $110.5K | $282.7K | $7.2M | $14.0M | $5.0M | $10.1M | $548.7K | $6.5M | $7.2M | $20.0M | |
| Operating Cash Flow | -$112.2K | -$716.4K | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M | -$13.4M | |
| Free Cash Flow | -$112.2K | -$716.4K | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M | -$13.4M | |
| Capital Expenditure | -$3.00 | $5.00 | -$20.1K | -$17.9K | -$5.7K | -$4.4K | -$3.9K | -$4.2K | -$18.2K | -$28.2K | |
| Financing Cash Flow | $222.7K | $1.2M | $10.3M | $14.1M | $4.5M | $15.6M | $4.6M | $23.0M | $14.6M | $21.3M |
R&D Spending
R&D (TTM)
$10.1M
R&D Intensity
—
R&D Growth vs Prior
+3.4%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $32.6K | $21.3K | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $10.1M | |
| SG&A | $182.5K | $860.5K | $2.0M | $4.4M | $4.7M | $5.6M | $4.8M | $5.6M | $6.2M | $6.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $2.0K | $11.1K | $13.1K | $11.8K | $4.1K | $3.3K | $0.00 | -$333.00 | |
| Gross Profit | $0.00 | $0.00 | -$2.0K | -$11.1K | -$13.1K | -$11.8K | -$4.1K | -$3.3K | $0.00 | $333.00 | |
| R&D | $32.6K | $21.3K | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $10.1M | |
| SG&A | $182.5K | $860.5K | $2.0M | $4.4M | $4.7M | $5.6M | $4.8M | $5.6M | $6.2M | $6.8M | |
| Operating Income | -$516.3K | -$881.8K | -$3.8M | -$9.5M | -$14.5M | -$14.9M | -$18.9M | -$14.9M | -$16.0M | -$16.9M | |
| Interest Expense | $4.3K | $46.7K | $44.2K | $3.3K | $9.3K | $7.0K | $13.8K | $16.1K | $15.2K | $14.9K | |
| Pretax Income | -$219.4K | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M | -$16.7M | |
| Net Income | -$526.5K | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M | -$16.7M | |
| EPS (Diluted) | -11997.00 | -404415.00 | -212121.00 | -512208.00 | -495027.00 | -336499.00 | -150114.00 | -466.44 | -35.75 | -23.59 | |
| EBITDA | -$513.9K | -$6.5M | -$3.8M | -$9.4M | -$14.5M | -$15.3M | -$18.8M | -$14.8M | -$15.8M | -$16.7M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.44 | 6.84 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.5K | $282.7K | $7.2M | $14.0M | $5.0M | $10.1M | $548.7K | $6.5M | $7.2M | $20.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $162.2K | $588.1K | $7.9M | $15.5M | $7.5M | $12.6M | $1.6M | $8.7M | $8.1M | $21.9M | |
| Total Assets | $162.2K | $683.3K | $7.9M | $15.9M | $8.8M | $13.1M | $1.7M | $8.7M | $8.6M | $21.9M | |
| Total Current Liabilities | $220.7K | $1.2M | $311.0K | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M | $3.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $220.7K | $1.2M | $311.0K | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M | $3.7M | |
| Stockholders' Equity | -$58.5K | -$549.3K | $7.6M | $13.9M | $6.6M | $8.1M | -$4.4M | $6.2M | $4.5M | $18.2M | |
| Retained Earnings | -$219.4K | -$7.6M | -$11.5M | -$20.9M | -$35.0M | -$50.7M | -$69.6M | -$84.4M | -$100.3M | -$107.8M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$112.2K | -$716.4K | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M | -$13.4M | |
| Capital Expenditure | -$3.00 | $5.00 | -$20.1K | -$17.9K | -$5.7K | -$4.4K | -$3.9K | -$4.2K | -$18.2K | -$28.2K | |
| Free Cash Flow | -$112.2K | -$716.4K | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M | -$13.4M | |
| Investing Cash Flow | $0.00 | $0.00 | -$20.1K | -$17.9K | -$5.7K | -$4.4K | -$3.9K | -$4.2K | -$18.2K | -$28.2K | |
| Financing Cash Flow | $222.7K | $1.2M | $10.3M | $14.1M | $4.5M | $15.6M | $4.6M | $23.0M | $14.6M | $21.3M | |
| Issuance of Stock | $100.9K | $390.5K | $10.3M | $14.2M | $4.7M | $16.0M | $2.3M | $23.4M | $14.0M | $21.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.0K | $0.00 | |
| Net Debt Issuance | $121.8K | $300.0K | -$35.0K | -$43.1K | -$477.5K | -$427.7K | -$438.7K | -$300.8K | -$297.6K | -$308.8K | |
| Stock Based Comp. | $119.9K | $110.2K | $477.1K | $1.3M | $1.7M | $1.2M | $1.0M | $839.0K | $187.7K | $108.5K | |
| Net Change in Cash | $110.5K | $444.6K | $6.7M | $6.8M | -$9.0M | $5.1M | -$9.5M | $5.9M | $739.6K | $7.9M |
Dilution Tracker
Shares outstanding grew 2463061.1% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+2463061.1%
Stock Issuance (TTM)
$21.7M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.44 | 6.84 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 61.1% | 55.2% | 180.0% | 25180.2% | 1291.9% | 1442.3% | |
| Stock Issuance | $100.9K | $390.5K | $10.3M | $14.2M | $4.7M | $16.0M | $2.3M | $23.4M | $14.0M | $21.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.0K | $0.00 | |
| Stock Based Comp. | $119.9K | $110.2K | $477.1K | $1.3M | $1.7M | $1.2M | $1.0M | $839.0K | $187.7K | $108.5K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 899.5% | 1345.7% | -51.0% | -67.8% | -218.9% | -187.8% | 425.3% | -240.5% | -350.5% | -204.3% | |
| ROA % | -324.6% | -1081.7% | -49.0% | -59.7% | -165.5% | -117.0% | -1108.3% | -170.8% | -183.8% | -76.1% | |
| ROIC % | -815.7% | 379.5% | -50.4% | -65.7% | -206.7% | -174.8% | 456.6% | -229.2% | -329.5% | -92.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -467.6% | -17.8% | 10.1% | 64.8% | 20.0% | 100.0% | |
| Operating Income | 0.0% | -70.8% | -334.7% | -146.7% | -53.2% | -3.1% | -26.3% | 21.0% | -7.3% | |
| Net Income | 0.0% | -1304.1% | 47.5% | -143.9% | -53.3% | -5.4% | -23.4% | 21.2% | -6.7% | |
| EPS (Diluted) | 0.0% | -3271.0% | 47.5% | -141.5% | 3.4% | 32.0% | 55.4% | 99.7% | 92.3% | |
| Operating Cash Flow | 0.0% | -538.5% | -396.0% | -105.9% | -85.0% | 22.0% | -33.9% | -21.0% | 19.3% | |
| Free Cash Flow | 0.0% | -538.5% | -398.8% | -105.3% | -84.6% | 22.0% | -33.9% | -21.0% | 19.2% | |
| R&D Expense | 0.0% | -34.8% | 8619.3% | 173.0% | 93.7% | -5.2% | 51.6% | -34.1% | 5.2% | |
| SG&A Expense | 0.0% | 371.6% | 129.7% | 121.7% | 6.5% | 20.4% | -15.2% | 17.6% | 10.8% | |
| Total Assets | 0.0% | 321.3% | 1057.9% | 100.4% | -44.8% | 49.1% | -87.0% | 411.6% | -0.9% | |
| Book Value / Share | 0.0% | -838.5% | 1483.8% | 83.5% | -70.5% | -20.8% | -119.5% | 100.6% | -94.7% | |
| Debt | 0.0% | 160.1% | -100.0% | 0.0% | -11.7% | 5.7% | -26.6% | 8.4% | 0.8% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 61.1% | 55.2% | 180.0% | 25180.2% | 1291.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.47
10Y Low / Med / High0.37 / 2.07 / 8.42
EV/EBITDA0.86
10Y Low / Med / High0.26 / 0.29 / 0.42
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$7.67
Tangible Book / Share
$2.66
Net Current Assets / Share
$12.44
Graham Net-Net
$2.38
Cash / Share
$2.92
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -342.84 | -10.17 | -16.76 | -3.13 | -1.28 | -0.21 | -0.25 | -0.15 | -0.15 | -0.17 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -1264.85 | -134.78 | 8.42 | 2.07 | 2.77 | 0.40 | -1.08 | 0.37 | 0.51 | 1.47 | |
| EV/EBITDA | -144.08 | -11.46 | -14.81 | -1.61 | -0.95 | 0.42 | -0.24 | 0.26 | 0.29 | 0.86 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-7.47
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $40.8M | $50.0M | $76.2M |
| Net Income | -$731.6K | -$736.0K | -$833.5K |
| EPS | $-1.65 | $-1.66 | $-1.88 |
| # Analysts (EPS) | 1 | 1 | 1 |